Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-056859
Filing Date
2024-05-09
Accepted
2024-05-09 16:03:59
Documents
73
Period of Report
2024-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q eftr-20240331.htm   iXBRL 10-Q 1485624
2 EX-31.1 eftr-ex31_1.htm EX-31.1 15500
3 EX-31.2 eftr-ex31_2.htm EX-31.2 15457
4 EX-32.1 eftr-ex32_1.htm EX-32.1 8507
5 EX-32.2 eftr-ex32_2.htm EX-32.2 8474
  Complete submission text file 0000950170-24-056859.txt   8481503

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT eftr-20240331.xsd EX-101.SCH 1722079
76 EXTRACTED XBRL INSTANCE DOCUMENT eftr-20240331_htm.xml XML 1403056
Mailing Address 142 NORTH CEDROS AVENUE, SUITE B SOLANA BEACH CA 92075
Business Address 142 NORTH CEDROS AVENUE, SUITE B SOLANA BEACH CA 92075 (858) 925-8215
eFFECTOR Therapeutics, Inc. (Filer) CIK: 0001828522 (see all company filings)

EIN.: 853306396 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39866 | Film No.: 24930360
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)